Figure 2.
Survival curves of patients with KITD816 t(8;21) AML, non-D816 KITpos t(8;21) AML, and SM-t(8;21) AML. (A-B) Kaplan-Meier curves of OS and EFS of patients with KITD816 t(8;21) AML, non-D816 KITpos t(8;21) AML, and SM-t(8;21) AML, respectively. The P value was calculated using log-rank test. (C-D) Simon-Makuch curves showing the impact of allo-HSCT on OS and EFS of patients with SM-t(8;21) AML, respectively. (E-F) Simon-Makuch curves showing the impact of allo-HSCT on OS and EFS of patients with KITD816 t(8;21) AML, respectively. (G-H) Simon-Makuch curves showing the impact of allo-HSCT on OS and EFS of patients with non-D816 KITpos t(8;21) AML, respectively. The P value was calculated using Mantel-Byar test. ns, not significant.

Survival curves of patients with KITD816 t(8;21) AML, non-D816 KITpos t(8;21) AML, and SM-t(8;21) AML. (A-B) Kaplan-Meier curves of OS and EFS of patients with KITD816 t(8;21) AML, non-D816 KITpos t(8;21) AML, and SM-t(8;21) AML, respectively. The P value was calculated using log-rank test. (C-D) Simon-Makuch curves showing the impact of allo-HSCT on OS and EFS of patients with SM-t(8;21) AML, respectively. (E-F) Simon-Makuch curves showing the impact of allo-HSCT on OS and EFS of patients with KITD816 t(8;21) AML, respectively. (G-H) Simon-Makuch curves showing the impact of allo-HSCT on OS and EFS of patients with non-D816 KITpos t(8;21) AML, respectively. The P value was calculated using Mantel-Byar test. ns, not significant.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal